ATYR Latest Press Releases

-- November 5, 2026 --

aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update Globe Newswire 4:01 PM

-- October 29, 2026 --

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine Globe Newswire 8:00 AM

-- October 27, 2026 --

aTyr Pharma Announces One-for-40 Reverse Stock Split Globe Newswire 9:00 AM

-- October 19, 2026 --

aTyr Pharma Announces Research Collaboration with Montefiore Einstein Globe Newswire 7:00 AM

-- October 13, 2026 --

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry Globe Newswire 8:00 AM

-- September 24, 2026 --

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis Globe Newswire 6:00 AM

-- September 1, 2026 --

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis Globe Newswire 4:36 PM

-- August 7, 2026 --

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD Globe Newswire 4:01 PM

-- July 15, 2026 --

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026 Globe Newswire 8:00 AM

-- June 26, 2026 --

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing Globe Newswire 8:35 AM

-- June 23, 2026 --

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th Globe Newswire 8:35 AM

Market Data Delayed 15 Minutes